Skip to main content
Daniel Haber, MD, Oncology, Boston, MA

DanielAHaberMDPhD

Oncology Boston, MA

Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor, Harvard Medical School

Dr. Haber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Haber's full profile

Already have an account?

  • Office

    55 Fruit St
    149 7202
    Boston, MA 02114
    Phone+1 617-726-7805
    Fax+1 617-724-6919

Education & Training

  • Massachusetts Institute of Technology
    Massachusetts Institute of TechnologyPost-Doctoral Fellowship, 1987 - 1991
  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1990
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1984 - 1986
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1983 - 1984
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1983

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1985 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member Fellow of the AACR Academy, 2019
  • Elected Member National Academy of Sciences, 2018
  • Investigator Howard Hughes Medical Institute
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer  
    David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research

Press Mentions

  • Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma
    Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in MelanomaMarch 16th, 2023
  • Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression
    Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis SuppressionOctober 24th, 2022
  • TellBio’s Scientific Founders Publish Very High Concordance Between CTCs and ctDNA from Liquid Biopsies in Patients with Breast Cancer
    TellBio’s Scientific Founders Publish Very High Concordance Between CTCs and ctDNA from Liquid Biopsies in Patients with Breast CancerJuly 15th, 2021
  • Join now to see all

Grant Support

  • Circumventing Acquired Resistance To Growth Factor Receptor Kinase InhibitorsNational Cancer Institute2008–2012
  • Data Production, And Informatics And IntegrationNational Human Genome Research Institute2010–2011
  • P1 - Clinical Correlations Of WTX Inactivation In Wilms TumorNational Cancer Institute2010–2011
  • Functional Properties Of The Wilms'Tumor Gene WT1National Cancer Institute2008–2011
  • Functional Properties Of The Wilms' Tumor Gene WT1National Cancer Institute2010
  • Clinical Correlations Of WTX Inactivation In Wilms TumorNational Cancer Institute2009
  • Functional Properties Of The Wilm'S Tumor Gene WT1National Cancer Institute2003–2007
  • Targets Of Ewing Sarcoma-Wilms Tumor 1 OncoproteinNational Cancer Institute2002–2006
  • Genetic Models Of Cellular ProliferationNational Cancer Institute2002–2006
  • Functional Characterization Of BRCA1National Cancer Institute2000–2004
  • Screen For Genes Targeted By Homozygous Deletion During Cancer ProgressionNational Cancer Institute2002
  • G2 Checkpoint Genes In Breast Cancer SusceptibiityNational Cancer Institute2000–2002
  • Functional Properties Of The Wilms Tumor Gene WT1National Cancer Institute1998–2002
  • Mutational Analysis Of P53 Related GenesNational Cancer Institute2000–2001
  • Isolation Of Gene For X-Linked LymphoproliferationNational Cancer Institute1995–1998
  • Mutational And Functional Analysis Of Wilm'S TumorNational Cancer Institute1994–1997
  • Mutational And Functional Analysis Of Wilms'TumorNational Cancer Institute1993
  • Multidrug Resistance Genes--Expression And FunctionNational Cancer Institute1990
  • Multidrug Resistance Genes--Expression And FunctionNational Cancer Institute1988–1989